Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1359

1.

Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.

Hemmingsen B, Schroll JB, Lund SS, Wetterslev J, Gluud C, Vaag A, Sonne DP, Lundstrøm LH, Almdal T.

Cochrane Database Syst Rev. 2013 Apr 30;(4):CD009008. doi: 10.1002/14651858.CD009008.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;(7):CD009008.

PMID:
23633364
2.
3.

Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.

Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP, Hemmingsen C, Wetterslev J.

Cochrane Database Syst Rev. 2013 Nov 11;(11):CD008143. doi: 10.1002/14651858.CD008143.pub3. Review. Update in: Cochrane Database Syst Rev. 2015;(7):CD008143.

PMID:
24214280
4.
5.

Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.

Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, Wetterslev J.

Cochrane Database Syst Rev. 2011 Jun 15;(6):CD008143. doi: 10.1002/14651858.CD008143.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;11:CD008143.

PMID:
21678374
6.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
7.

Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.

Vos RC, van Avendonk MJ, Jansen H, Goudswaard AN, van den Donk M, Gorter K, Kerssen A, Rutten GE.

Cochrane Database Syst Rev. 2016 Sep 18;9:CD006992. [Epub ahead of print] Review.

PMID:
27640062
8.

Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.

Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A.

Cochrane Database Syst Rev. 2014 Feb 14;(2):CD009122. doi: 10.1002/14651858.CD009122.pub2. Review.

PMID:
24526393
9.

Metformin monotherapy for type 2 diabetes mellitus.

Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002966. Review. Update in: Cochrane Database Syst Rev. 2015;9:CD002966.

PMID:
16034881
10.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
11.

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.

Hauser G, Awad T, Brok J, Thorlund K, Štimac D, Mabrouk M, Gluud C, Gluud LL.

Cochrane Database Syst Rev. 2014 Feb 28;(2):CD005441. Review.

PMID:
24585509
12.

Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.

Lombardi R, Onali S, Thorburn D, Davidson BR, Gurusamy KS, Tsochatzis E.

Cochrane Database Syst Rev. 2017 Mar 30;3:CD011640. doi: 10.1002/14651858.CD011640.pub2. Review.

PMID:
28358980
13.

Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.

Gluud LL, Vilstrup H, Morgan MY.

Cochrane Database Syst Rev. 2016 Apr 18;4:CD003044. doi: 10.1002/14651858.CD003044.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;(5):CD003044.

PMID:
27089005
14.

Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.

Gluud LL, Vilstrup H, Morgan MY.

Cochrane Database Syst Rev. 2016 May 6;(5):CD003044. doi: 10.1002/14651858.CD003044.pub4. Review.

PMID:
27153247
15.

Nitazoxanide for chronic hepatitis C.

Nikolova K, Gluud C, Grevstad B, Jakobsen JC.

Cochrane Database Syst Rev. 2014 Apr 6;(4):CD009182. doi: 10.1002/14651858.CD009182.pub2. Review.

PMID:
24706397
16.

Non-steroid anti-inflammatory drugs for biliary colic.

Fraquelli M, Casazza G, Conte D, Colli A.

Cochrane Database Syst Rev. 2016 Sep 9;9:CD006390. [Epub ahead of print] Review.

17.

Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses.

Hemmingsen B, Christensen LL, Wetterslev J, Vaag A, Gluud C, Lund SS, Almdal T.

BMJ. 2012 Apr 19;344:e1771. doi: 10.1136/bmj.e1771. Review.

PMID:
22517929
18.

Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients.

Penninga L, Wettergren A, Wilson CH, Chan AW, Steinbrüchel DA, Gluud C.

Cochrane Database Syst Rev. 2014 Jun 5;(6):CD010253. doi: 10.1002/14651858.CD010253.pub2. Review.

PMID:
24901467
19.

Nutrition support in hospitalised adults at nutritional risk.

Feinberg J, Nielsen EE, Korang SK, Halberg Engell K, Nielsen MS, Zhang K, Didriksen M, Lund L, Lindahl N, Hallum S, Liang N, Xiong W, Yang X, Brunsgaard P, Garioud A, Safi S, Lindschou J, Kondrup J, Gluud C, Jakobsen JC.

Cochrane Database Syst Rev. 2017 May 19;5:CD011598. doi: 10.1002/14651858.CD011598.pub2. Review.

PMID:
28524930
20.

Ursodeoxycholic acid for primary biliary cirrhosis.

Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD000551. doi: 10.1002/14651858.CD000551.pub3. Review.

PMID:
23235576

Supplemental Content

Support Center